Memory improvement with a new peptide for moderate dementia
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a new peptide (a small protein fragment) called PMS-001 can improve long-term memory in people with moderate to severe dementia. It is an early stage trial, so it will help determine if the drug is safe and if it has any effect on recall.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 60 and 80 years old
- Your dementia must be moderate to severe (not mild)
- You must be able to read, hear, and speak well enough to complete memory tests
- You must not have other brain diseases (like stroke or Parkinson's) that cause memory loss
- You must not have severe depression or other major psychiatric conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
This trial studies a non-medication (non-drug) program to improve memory and daily thinking in people with mild cognitive impairment or mild Alzheimer’s disease. It may help by supporting brain function and monitoring symptoms over time.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
This study tests whether a medicine called NPC-1 can help people with mild memory or thinking problems or early-stage Alzheimer's. It looks at a blood marker to see if the treatment may slow down the disease.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.